Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Flanagan

Showing results (31-40 of 643) with videos related to

Pageof 65
Sort By:
The Lancet Regional Health. Western Pacific|February 3, 2022
Understanding the etiology and epidemiology of meningitis and encephalitis: now and into the futureVyanka Redenbaugh, Eoin P Flanagan
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 10, 2022
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGADVyanka Redenbaugh, Eoin P Flanagan
Chemistry and Physics of Lipids|August 1, 1995
Mass spectrometric evidence for the anomalous chemical behavior of 11-dehydrothromboxane B2A Ferretti, V P Flanagan
BMJ (Clinical Research Ed.)|June 13, 1992
Deaths from hemolytic disease of the newbornG J Dovey, P Flanagan
The Ulster Medical Journal|September 18, 1999
Acute medical bed usage by nursing home residentsT R Beringer, P Flanagan
BMJ (Clinical Research Ed.)|March 28, 1992
Patients with secondary polycythaemia as blood donorsP S Rawlinson, P Flanagan
Neurology(R) Neuroimmunology & Neuroinflammation|November 18, 2025
Expanding Evidence of Leptomeningeal Involvement in MOGAD and Its Relevance to Its PathophysiologyLaura Cacciaguerra, Eoin P Flanagan
Biochimica Et Biophysica Acta|August 6, 1990
Modification of prostaglandin metabolism in vivo by long-chain omega-3 polyunsaturatesA Ferretti, V P Flanagan
Lipids|May 1, 1979
Simultaneous mass spectrometric measurement of prostaglandins E1 (PGE1) and PGE2 with a deuterated internal standardA Ferretti, V P Flanagan
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 25, 2025
Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and howAdrian Budhram, Eoin P Flanagan
Pageof 65

Showing results (31-40 of 643) with videos related to

Sort By:
Pageof 65
The Lancet Regional Health. Western Pacific|February 3, 2022
Understanding the etiology and epidemiology of meningitis and encephalitis: now and into the futureVyanka Redenbaugh, Eoin P Flanagan
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|March 10, 2022
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGADVyanka Redenbaugh, Eoin P Flanagan
Chemistry and Physics of Lipids|August 1, 1995
Mass spectrometric evidence for the anomalous chemical behavior of 11-dehydrothromboxane B2A Ferretti, V P Flanagan
BMJ (Clinical Research Ed.)|June 13, 1992
Deaths from hemolytic disease of the newbornG J Dovey, P Flanagan
The Ulster Medical Journal|September 18, 1999
Acute medical bed usage by nursing home residentsT R Beringer, P Flanagan
BMJ (Clinical Research Ed.)|March 28, 1992
Patients with secondary polycythaemia as blood donorsP S Rawlinson, P Flanagan
Neurology(R) Neuroimmunology & Neuroinflammation|November 18, 2025
Expanding Evidence of Leptomeningeal Involvement in MOGAD and Its Relevance to Its PathophysiologyLaura Cacciaguerra, Eoin P Flanagan
Biochimica Et Biophysica Acta|August 6, 1990
Modification of prostaglandin metabolism in vivo by long-chain omega-3 polyunsaturatesA Ferretti, V P Flanagan
Lipids|May 1, 1979
Simultaneous mass spectrometric measurement of prostaglandins E1 (PGE1) and PGE2 with a deuterated internal standardA Ferretti, V P Flanagan
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 25, 2025
Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and howAdrian Budhram, Eoin P Flanagan
Pageof 65